Completed
Phase 2: Antitumor Activity of Thalidomide in Refractory Multiple Myeloma - NEJM 1999
Time Frame: December 1997 and June 1998
Phase 2: Antitumor Activity of Thalidomide in Refractory Multiple Myeloma - NEJM 1999
Antitumor Activity of Thalidomide in Refractory Multiple Myeloma
Seema Singhal, M.D., Jayesh Mehta, M.D., Raman Desikan, M.D., Dan Ayers, M.S., Paula Roberson, Ph.D., Paul Eddlemon, B.S., Nikhil Munshi, M.D., Elias Anaissie, M.D., Carla Wilson, M.D., Ph.D., Madhav Dhodapkar, M.D., Jerome Zeldis, M.D., David Siegel, M.D., Ph.D., John Crowley, Ph.D., and Bart Barlogie, M.D., Ph.D.
NEJM - November 18, 1999
Phase 2: Antitumor Activity of Thalidomide in Refractory Multiple Myeloma - NEJM 1999
Archives NY Times - Beth Wolmer / Ira Wolmer, M.D.
Thalidomide Found to Slow a Bone Cancer